Chronic infection with *Helicobacter pylori*, *Chlamydia pneumoniae*, or cytomegalovirus: population based study of coronary heart disease

J Danesh, Y Wong, M Ward, J Muir

Abstract

**Objective**—To study possible associations between coronary heart disease and serological evidence of persistent infection with *Helicobacter pylori*, *Chlamydia pneumoniae*, or cytomegalovirus.

**Design**—Population based, case-control study, nested within a randomised trial.

**Setting**—Five general practices in Bedfordshire, UK.

**Individuals**—288 patients with incident or prevalent coronary heart disease and 704 age and sex matched controls.

**Results**—High concentrations of serum IgG antibodies to *H pylori* were present in 54% of cases vs 46% of controls, with corresponding results for *C pneumoniae* seropositivity (33% vs 33%), and cytomegalovirus seropositivity (40% vs 31%). After adjustments for age, sex, smoking, indicators of socioeconomic status, and standard risk factors, the odds ratios (95% confidence intervals) for coronary heart disease of seropositivity to these agents were: 1.28 (0.93 to 1.75) for *H pylori*, 0.95 (0.66 to 1.36) for *C pneumoniae*, and 1.40 (0.96 to 2.05) for cytomegalovirus.

**Conclusions**—There is no good evidence of strong associations between coronary heart disease and serological markers of persistent infection with *H pylori*, *C pneumoniae*, or cytomegalovirus. To determine the existence of moderate associations between these agents and disease, however, larger scale studies will be needed that can keep residual confounders to a minimum.

(Heart 1999; 81:245–247)

**Keywords:** ischaemic heart disease; *Helicobacter pylori*; *Chlamydia pneumoniae*; cytomegalovirus

It has been suggested that coronary heart disease may be associated with persistent bacterial or viral agents. Further studies have raised the possibility that anti-infective treatments, such as a short course of antibiotics, might be able to prevent disease. Most studies have involved measurements for bacterial or viral agents.

It has been suggested that coronary heart disease may be associated with persistent bacterial or viral agents. Further studies have raised the possibility that anti-infective treatments, such as a short course of antibiotics, might be able to prevent disease. Most studies have involved measurements for bacterial or viral agents.

Methods

**PARTICIPANTS AND LABORATORY METHODS**

In the early 1990s, 8100 volunteers aged 35 to 64 years at entry to a trial of nurse health checks in five Bedfordshire general practices completed questionnaires and gave non-fasting venous blood samples that were centrifuged and stored at −80°C within 24 hours after venesection. Practice nurses took measurements of participants’ height, weight, and blood pressure. For the present study, cases were defined on the basis of incident coronary heart disease death (n = 76) notified by national mortality statistics following entry to the trial (average follow up four years), or on the basis of self reported coronary heart disease at the baseline interview (103 cases with a history of myocardial infarction, and 109 with angina but no myocardial infarction) that could be verified by systematic searches of the medical notes by research nurses. Cases with more than one manifestation of coronary heart disease were classified by their most severe disease (that is, coronary heart disease death > myocardial infarction > angina). We randomly selected 704 people without a history of coronary heart disease from among the trial participants to match the cases on sex and age (within five years). Operators unaware of the case-control status of the blood samples measured serum lipid concentrations using standard assays, and IgG antibodies to *H pylori* using a commercial kit (Orion; Pyloriset, Espoo, Finland), to *C pneumoniae* (whole organism antigen), and to cytomegalovirus (whole organism antigen) using time resol ved fluorimetry (Delfia; Wallac, Turku, Finland). The coefficients of variation within and between assays for the infective agents were about 4% and 18%, respectively. A validation study in 480 individuals from another study indicated good agreement with standard microimmunofluorescence for *C pneumoniae* antibodies.

**STATISTICS**

The distribution of *C pneumoniae* titres was approximately normal, and cytomegalovirus titre distribution was approximately bimodal. As there are no generally agreed cut offs for seropositivity to *C pneumoniae* or cytomegalovirus antibodies, analysis by thirds of titres was...
Table 1  Baseline characteristics of cases and controls

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Cases (n = 288)</th>
<th>Controls (n = 704)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Questionnaire</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (years)</td>
<td>59.2 (5.9)</td>
<td>59.0 (6.1)</td>
<td>Matched</td>
</tr>
<tr>
<td>Male</td>
<td>200 (69%)</td>
<td>475 (67%)</td>
<td>Matched</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.4 (4.4)</td>
<td>26.1 (3.8)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Current smokers</td>
<td>155 (54%)</td>
<td>278 (39%)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Treated hypertensives</td>
<td>23 (8%)</td>
<td>23 (3%)</td>
<td>0.001</td>
</tr>
<tr>
<td>Treated diabetics</td>
<td>133 (46%)</td>
<td>124 (18%)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Blood sample</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol (mmol/l)</td>
<td>6.58 (1.65)</td>
<td>6.33 (1.24)</td>
<td>0.007</td>
</tr>
<tr>
<td>Low density lipoprotein cholesterol (mmol/l)</td>
<td>3.69 (1.75)</td>
<td>3.67 (1.48)</td>
<td>NS</td>
</tr>
<tr>
<td>High density lipoprotein cholesterol (mmol/l)</td>
<td>1.18 (0.44)</td>
<td>1.30 (0.42)</td>
<td>&lt; 0.00001</td>
</tr>
<tr>
<td>Triglycerides (mmol/l)</td>
<td>2.48 (1.40)</td>
<td>2.15 (1.33)</td>
<td>0.0003</td>
</tr>
</tbody>
</table>

Values are mean (SD) unless otherwise stated.

Discussion

More than 70 seroepidemiological studies have reported on associations between coronary heart disease and chronic infection with *H pylori*, *C pneumoniae*, or cytomegalovirus. Most, however, have been based on small sample sizes, involved opportunistic control groups prone to selection biases, made few adjustments for possible confounders, and involved opportunistic control groups. It seems likely that chance effects, or the preferential publication of more extreme associations (that is, “publication bias”), or both, may at least partly account for the generally larger odds ratios reported in smaller studies without appropriate adjustment for confounders than in larger studies with population based controls. It therefore remains uncertain whether infection with any of these agents is really associated with coronary heart disease.

Our present population based, case–control study of 288 cases involved adjustment for standard vascular risk factors and several indicators of socioeconomic status. It confirmed the tendency to less extreme results in more reliable epidemiological studies of persistent infections and coronary heart disease, as we observed no strong association of coronary heart disease with levels of serum IgG antibodies to *H pylori*, *C pneumoniae*, or cytomegalovirus. For *H pylori*, the adjusted odds ratio of 1.3 is compatible with the findings of a meta-analysis of four long term prospective reports involving a total 1441 cases that yielded a combined risk ratio of 1.2 for coronary heart disease death or myocardial infarction (95% confidence interval 1.0 to 1.4). Evidence for a moderate association between *H pylori* and coronary heart disease is, however, difficult to interpret even in population based studies, particularly as residual confounding by factors (table 2), but adjustment for serum lipids, blood pressure, and other standard risk factors had little effect. None of the adjusted associations of coronary heart disease with serological evidence of these infections was highly significant. Varying the cut off for seropositivity around the prespecified levels for each agent did not change the estimates substantially. The data are too sparse to subdivide results reliably by possibly relevant characteristics, such as coronary heart disease type (for example, incident v prevalent cases) or the presence of co-infections.

Table 2  Prevalence of seropositivity for antibodies to some chronic infective agents

<table>
<thead>
<tr>
<th>Agent</th>
<th>Seropositive*</th>
<th>Seronegative*</th>
<th>Odds ratio and 95% confidence interval</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Cases</td>
<td>Controls</td>
<td>Adjusted for age and sex only</td>
</tr>
<tr>
<td><em>H pylori</em></td>
<td>134</td>
<td>294</td>
<td>1.41 (1.05 to 1.90)</td>
</tr>
<tr>
<td><em>C pneumoniae</em></td>
<td>94</td>
<td>234</td>
<td>1.04 (0.74 to 1.48)</td>
</tr>
<tr>
<td>Cytomegalovirus</td>
<td>114</td>
<td>221</td>
<td>1.57 (1.11 to 2.22)</td>
</tr>
</tbody>
</table>

*For *C pneumoniae* and cytomegalovirus antibodies, analysis by thirds of titres was prespecified—that is, seropositive samples were defined as those in the top third of the distribution, and seronegative samples as those in the bottom third, whereas manufacturer’s recommended cut off was used to determine *H pylori* sensitivity.
†Cigarette smoking (current, ex, never; number of cigarettes/day), markers of socioeconomic status (age at stopping education; occupation; housing tenure; car ownership; marital status; employment status), non-fasting serum total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, triglycerides, resting systolic and diastolic blood pressures, body mass index, and previous history of diabetes.
related to socioeconomic status is likely. For *C. pneumoniae*, the three previously reported prospective seroepidemiological studies of coronary heart disease death or myocardial infarction (358 cases in all) collectively suggest a weakly positive association, albeit with very wide confidence limits, whereas the largest retrospective population based study of 302 cases did not report a positive association (and in fact it reported a non-significant inverse association). The estimate of the present study (odds ratio 1.0 (0.7 to 1.4)) is compatible with either no association or with a weakly positive association of *C. pneumoniae* seropositivity with coronary heart disease. With regard to cytomegalovirus, most of the previously reported studies have involved cases defined on the basis of vascular disease outside the coronary circulation or in transplanted hearts or coronary restenosis. Our study doubles the available information from population based studies on cytomegalovirus and classic coronary heart disease, and it does not suggest that there are strong associations.

The present study, together with the largely previously reported population based studies, suggests that the infective agents described in this report are unlikely to be strongly associated with coronary heart disease. It may still be important, however, to make a reliable assessment of possible moderate associations between these agents and coronary heart disease (for example, odds ratios < 1.5), particularly if anti-infective interventions might be able to prevent some disease. Such studies would require substantially larger sample sizes than reported in available studies, as well as socially homogeneous populations to keep residual confounders to a minimum. Also, serial antibody measurements would help to correct for underestimation caused by fluctuations of serum antibody titres within individuals over time (especially for agents such as *C. pneumoniae* and cytomegalovirus, which are prone to reinfection and reactivation, respectively). Results from such studies should be more informative than existing reports, particularly if they involve cases at younger ages where any real association between infections and coronary heart disease might be stronger than at older ages.

Alice Fuller helped with data management, and Jenny Jay and Janet Robertson audited clinical notes and retrieved blood samples. JD is supported by a Merton College Junior Research Fellowship and a Frohlich award; YW and MW are supported by the British Heart Foundation and the Wessex Heartbeat Trust.